Background: Colorectal cancer (CRC) is a type of neoplasm, developing in the colon or rectum. The exact etiology of CRC is not well known, but the role of genetic, epigenetic, and environmental factors are established in its pathogenesis. Therefore, the aim of this research was to explore the effects of ANRIL polymorphisms on the CRC and its clinical ndings.Methods and Results: The peripheral blood specimens were collected from 142 CRC patients and 225 controls referred to Milad Hospital, Tehran, Iran. PCR-RFLP method was used to analyze ANRIL rs1333040 rs10757274, rs10757274 and rs1333048 polymorphisms. The ANRIL rs1333040 polymorphism was related to a higher risk of CRC in the co-dominant, dominant, and log-additive models. ANRIL rs10757274, rs10757274, and rs1333048 polymorphisms showed no effect on CRC susceptibility. Haplotype analysis showed a higher risk of CRC in individuals carrying the CGAA haplotype of ANRIL rs1333040/ rs10757274/ rs4977574/rs1333048 polymorphisms and a lower risk of TGGA haplotype compared to TGGC haplotype. The rs1333040 polymorphism was associated with higher TNM stages (III and IV). ANRIL rs10757274 polymorphism was lower in CRC patients over the age of 50 years only in the dominant model. In addition, the rs10757274 was associated with well differentiation in CRC patients.Conclusion, The ANRIL rs1333040 polymorphism was associated with a higher risk of CRC and higher TNM stages. ANRIL rs10757274 polymorphism was associated with the well-differentiated tumor in CRC.